Read by QxMD icon Read

ross baldessarini

Mario Biagiarelli, Martina Curto, Ileana Di Pomponio, Anna Comparelli, Ross J Baldessarini, Stefano Ferracuti
The Rorschach-based Perceptual Thinking Index (PTI) is used to identify and rate features of psychotic disorders, but effects of antipsychotic treatment on such ratings is not clear. Accordingly, we examined potential effects of antipsychotic drugs on PTI measures in 114 patients with a psychotic or bipolar-I disorder. Use and doses of antipsychotic drugs (as chlorpromazine-equivalent [CPZ-eq] mg/day) were unrelated to PTI total or subscale scores in any diagnostic group. PTI scores were independently and significantly associated with psychotic symptomatic severity (PANSS score) and less with female sex...
May 2017: Psychiatry Research
Ross J Baldessarini, Alberto Forte, Valerio Selle, Kang Sim, Leonardo Tondo, Juan Undurraga, Gustavo H Vázquez
No abstract text is available yet for this article.
2017: Psychotherapy and Psychosomatics
Maurizio Pompili, Monica Vichi, Enrico Dinelli, Denise Erbuto, Roger Pycha, Gianluca Serafini, Gloria Giordano, Paolo Valera, Stefano Albanese, Annamaria Lima, Benedetto De Vivo, Domenico Cicchella, Zoltan Rihmer, Andrea Fiorillo, Mario Amore, Paolo Girardi, Ross J Baldessarini
Arsenic, as a toxin, may be associated with higher mortality rates, although its relationship to suicide is not clear. Given this uncertainty, we evaluated associations between local arsenic concentrations in tapwater and mortality in regions of Italy, to test the hypothesis that both natural-cause and suicide death rates would be higher with greater trace concentrations of arsenic. Arsenic concentrations in drinking-water samples from 145 sites were assayed by mass spectrometry, and correlated with local rates of mortality due to suicide and natural causes between 1980 and 2011, using weighted, least-squares univariate and multivariate regression modeling...
March 2017: Psychiatry Research
Kamini Rajaratnam, Yu-Tao Xiang, Adarsh Tripathi, Helen F K Chiu, Tian-Mei Si, Kok-Yoon Chee, Ajit Avasthi, Sandeep Grover, Mian-Yoon Chong, Hironori Kuga, Shigenobu Kanba, Yan-Ling He, Min-Soo Lee, Shu-Yu Yang, Pichet Udomratn, Roy A Kallivayalil, Andi J Tanra, Margarita M Maramis, Winston W Shen, Norman Sartorius, Ee-Heok Kua, Chay-Hoon Tan, Rathi Mahendran, Naotaka Shinfuku, Min Yi Sum, Ross J Baldessarini, Kang Sim
OBJECTIVE: As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. METHODS: This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling...
April 2017: Journal of Clinical Psychopharmacology
Ross J Baldessarini, Marco Innamorati, Denise Erbuto, Gianluca Serafini, Andrea Fiorillo, Mario Amore, Paolo Girardi, Maurizio Pompili
BACKGROUND: Affective temperaments are associated with suicidal risk, but their predictive value relative to diagnosis of major affective disorder is uncertain. METHODS: We compared diagnoses, affective-temperament ratings (TEMPS-A), and other potential risk factors in 956 psychiatric inpatients, using bivariate analyses and multivariable logistic regression modeling for associations with suicidal status. RESULTS: Lifetime suicide-attempt rates were high (43...
December 13, 2016: Journal of Affective Disorders
Kamini Rajaratnam, Yu-Tao Xiang, Adarsh Tripathi, Helen Fung Kum Chiu, Tian-Mei Si, Kok-Yoon Chee, Ajit Avasthi, Sandeep Grover, Mian-Yoon Chong, Hironori Kuga, Shigenobu Kanba, Yan-Ling He, Min-Soo Lee, Shu-Yu Yang, Pichet Udomratn, Roy Abraham Kallivayalil, Andi J Tanra, Margarita Maramis, Winston Wu-Dien Shen, Norman Sartorius, Ee-Heok Kua, Chay-Hoon Tan, Rathi Mahendran, Naotaka Shinfuku, Min Yi Sum, Ross J Baldessarini, Kang Sim
In this study, we sought to examine factors associated with dosing of antidepressants (ADs) in Asia. Based on reported data and clinical experience, we hypothesized that doses of ADs would be associated with demographic and clinical factors and would increase over time. This cross-sectional, pharmacoepidemiological study analyzed data collected within the Research Study on Asian Psychotropic Prescription Pattern for Antidepressants from 4164 participants in 10 Asian countries, using univariate and multivariate methods...
December 2016: Journal of Clinical Psychopharmacology
Maurizio Pompili, Ross J Baldessarini, Alberto Forte, Denise Erbuto, Gianluca Serafini, Andrea Fiorillo, Mario Amore, Paolo Girardi
Modern antipsychotic drugs are employed increasingly in the treatment of mood disorders as well as psychoses, stimulating interest in their possible contributions to altering suicidal risk. Clozapine remains the only treatment with an FDA-recognized indication for reducing suicidal risk (in schizophrenia). We carried out a systematic, computerized search for reports of studies involving antipsychotic drug treatment and suicidal behaviors. A total of 19 reports provide data with preliminary support for potential suicide risk-reducing effects of olanzapine, quetiapine, ziprasidone, aripiprazole, and asenapine in addition to clozapine, and provide some support for antipsychotic drug treatment in general...
October 11, 2016: International Journal of Molecular Sciences
Ying Jiao Zhao, Liang Lin, Monica Teng, Ai Leng Khoo, Lay Beng Soh, Toshiaki A Furukawa, Ross J Baldessarini, Boon Peng Lim, Kang Sim
BACKGROUND: For treatment of patients diagnosed with schizophrenia, comparative long-term effectiveness of antipsychotic drugs to reduce relapses when minimising adverse effects is of clinical interest, hence prompting this review. AIMS: To evaluate the comparative long-term effectiveness of antipsychotic drugs. METHOD: We systematically searched electronic databases for reports of randomised controlled trials (RCTs) of antipsychotic monotherapy aimed at reducing relapse risks in schizophrenia...
January 2016: BJPsych Open
Giulia Serra, Athanasios Koukopoulos, Lavinia De Chiara, Flavia Napoletano, Alexia Koukopoulos, Gabriele Sani, Gianni L Faedda, Paolo Girardi, Daniela Reginaldi, Ross J Baldessarini
The objective of this study was to identify the predictive value of juvenile factors for adult suicidal behavior. We reviewed clinical records to compare factors identified in childhood and adolescence between adult suicidal versus nonsuicidal major affective disorder subjects. Suicide attempts occurred in 23.1% of subjects. Age-at-first-symptom was 14.2 vs. 20.2 years among suicidal versus nonsuicidal subjects (p < 0.0001). More prevalent in suicidal versus non-suicidal subjects by multivariate analysis were: depressive symptoms, hyper-emotionality, younger-at-first-affective-episode, family suicide history, childhood mood-swings, and adolescence low self-esteem...
September 27, 2016: Archives of Suicide Research: Official Journal of the International Academy for Suicide Research
Leonardo Tondo, Ross J Baldessarini
Suicidal behavior is strongly associated with depression, especially if accompanied by behavioral activation, dysphoria, or agitation. It may respond to some treatments, but the design of scientifically sound, ethical trials to test for therapeutic effects on suicidal behavior is highly challenging. In bipolar disorder, and possibly also unipolar major depression, an underprescribed medical intervention with substantial evidence of preventive effects on suicidal behavior is long-term treatment with lithium...
September 2016: Current Psychiatry Reports
Mauricio Tohen, Hari-Mandir K Khalsa, Paola Salvatore, Carlos A Zarate, Stephen M Strakowski, Jesús Pérez Sanchez-Toledo, Ross J Baldessarini
BACKGROUND: Early course in contemporary, clinically treated, nonaffective psychotic disorders other than schizophrenia remains incompletely defined. METHODS: We prospectively, repeatedly, and systematically assessed 114 patients hospitalized for a first episode of DSM-IV-TR nonaffective psychotic illness for ≥ 2 years (1989-1996) using structured (Structured Clinical Interview for DSM-III-R, Patient Edition; Clinical Global Impressions scale; Scale for the Assessment of Negative Symptoms; Scale for the Assessment of Positive Symptoms; and the expanded version of the Brief Psychiatric Rating Scale) and unstructured (best-estimate procedure, life charting) naturalistic follow-up procedures and survival analysis...
June 2016: Journal of Clinical Psychiatry
Martina Curto, Nicoletta Girardi, Luana Lionetto, Giuseppino M Ciavarella, Stefano Ferracuti, Ross J Baldessarini
Clozapine is exceptionally effective in psychotic disorders and can reduce suicidal risk. Nevertheless, its use is limited due to potentially life-threatening adverse effects, including myocarditis and cardiomyopathy. Given their clinical importance, we systematically reviewed research on adverse cardiac effects of clozapine, aiming to improve estimates of their incidence, summarize features supporting their diagnosis, and evaluate proposed monitoring procedures. Incidence of early (≤2 months) myocarditis ranges from <0...
July 2016: Current Psychiatry Reports
Ross J Baldessarini, Gustavo H Vázquez, Leonardo Tondo
BACKGROUND: Clinical characteristics proposed to be associated with suicidal risk include affective temperament types. We tested this proposal with two methods in a large sample of subjects with mood and anxiety disorders. METHODS: We assessed consecutive, consenting subjects clinically for affective temperament types and by TEMPS-A self-ratings for associations of temperament with suicidal ideation and acts, using standard bivariate methods, and multivariate logistic regression models...
July 1, 2016: Journal of Affective Disorders
Andrés Yanzón de la Torre, Nicolás Oliva, Paula L Echevarrieta, Bibiana G Pérez, Gabriela B Caporusso, Anabella J Titaro, Alejandro Todaro Kicyla, Mariana Cuatz, Mariana Locatelli, Lucila M Nelson, Mercedes Mac Mullen, Ross J Baldessarini, Federico M Daray
BACKGROUND: Depression is not uncommon among medically hospitalized patients, though reported prevalence has varied widely, often in samples involving elderly patients with particular illnesses. Accordingly, we evaluated risk of major depression in three metropolitan general hospitals in Buenos Aires, in subjects with a range of medical disorders and ages, comparing several standard screening methods to expert clinical examinations. METHODS: Consecutively hospitalized general medical patients were evaluated over a six-months...
June 2016: Journal of Affective Disorders
Ross J Baldessarini, Leonardo Tondo, Caterina Visioli, Gustavo H Vázquez
BACKGROUND: There is suggestive evidence that prior illness history may have little association with response to long-term treatment in bipolar disorder (BD) or recurrent major depressive disorder (MDD), but relationships of illness-history to treatment-response in acute episodes of depression require further testing. METHODS: We tested for associations of selected measures of illness history with remission during treatment of an acute index episode of major depression in 515 mood-disorder patients (327 MDD, 188 BD), using bivariate and multivariate methods...
February 2016: Journal of Affective Disorders
Habibollah Arefian, Stefan Hagel, Steffen Heublein, Florian Rissner, André Scherag, Frank Martin Brunkhorst, Ross J Baldessarini, Michael Hartmann
BACKGROUND: Health care-associated infections (HAIs) can be associated with increased health care costs. We examined extra length of hospital stay (LOS) and associated per diem costs attributable to HAIs in a large academic medical center. METHODS: Data for analysis were acquired in a preinterventional phase of a prospective cohort study (ALERTS) conducted over 12 months in 27 general and 4 intensive care units at Jena University Hospital. HAIs were identified among patients hospitalized for ≥48 hours with at least 1 risk factor for HAI and new antimicrobial therapy; the diagnosis was confirmed by U...
February 2016: American Journal of Infection Control
Shi Hui Poon, Kang Sim, Ross J Baldessarini
Bipolar disorder is prevalent, with high risks of disability, substance abuse and premature mortality. Treatment responses typically are incomplete, especially for depressive components, so that many cases can be considered "treatment resistant." We reviewed reports on experimental treatments for such patients: there is a striking paucity of such research, mainly involving small incompletely controlled trials of add-on treatment, and findings remain preliminary. Encouraging results have been reported by adding aripiprazole, bupropion, clozapine, ketamine, memantine, pramipexole, pregabalin, and perhaps tri-iodothyronine in resistant manic or depressive phases...
2015: Current Neuropharmacology
Ross J Baldessarini, Wai Keat Lau, Jordan Sim, Min Yi Sum, Kang Sim
No abstract text is available yet for this article.
September 13, 2015: International Journal of Neuropsychopharmacology
Adele C Viguera, Nicholas Milano, Ralston Laurel, Nicolas R Thompson, Sandra D Griffith, Ross J Baldessarini, Irene L Katzan
BACKGROUND: Patient-reported data can improve clinical care, including identifying patients who are at risk for suicide. METHODS: In a tertiary care, psychiatric outpatient clinic, we compared computerized self-assessments of suicidal risk based on item 9 of the Patient Health Questionnaire-9 and an electronic version of the Columbia Suicide Severity Rating Scale (C-SSRS), using retrospective medical record review of clinical psychiatric assessments as the reference standard...
September 2015: Psychosomatics
Paul A Vöhringer, Michael J Ostacher, Rif S El-Mallakh, Niki S Holtzman, Sairah B Thommi, Elizabeth A Whitham, Matthew C Sullivan, Claudia F Baldassano, Fredrick K Goodwin, Ross J Baldessarini, S Nassir Ghaemi
BACKGROUND: We sought to test the hypothesis that antidepressants (ADs) may show preferential efficacy and safety among patients with type II bipolar disorder (BD, BD-II) more than patients with type I BD (BD-I). METHODS: Patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, BD-I (n = 21) and BD-II (n = 49) in acute major depressive episodes were treated with ADs plus mood stabilizers to euthymia sustained for 2 months and then randomized openly to continue or discontinue ADs for up to 3 years...
October 2015: Journal of Clinical Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"